Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Verbal Short Term Memory
研究概览
简要总结
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),
排除标准
- •Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.
研究组 & 干预措施
Cannabidiol
干预措施: Cannabidiol (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Verbal Short Term Memory
时间窗: 6 weeks
Verbal short term memory is measured through the Hopkins Verbal Learning Test. Each trial has a max total score of 12 (range of 0-12), and the max total score for all three trials is 36 (range of 0-36). However, the data listed below is reported in the form of a t-score, with a higher score representing better verbal learning. These t-score values are normalizing the scores to populations, comparing them to a representative sample, with a mean of 50.
次要结局
- Overall Cognition as Measured on the MATRICS Battery(6 weeks)
研究者
Mohini Ranganathan
Assistant Professor
Yale University